• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Baker Bros. Advisors Lp sold $110,582 worth of shares (274,739 units at $0.40) (SEC Form 4)

    10/23/23 4:49:08 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BAKER BROS. ADVISORS LP

    (Last) (First) (Middle)
    860 WASHINGTON STREET, 3RD FLOOR

    (Street)
    NEW YORK NY 10014

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Atreca, Inc. [ BCEL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Former 10% Owner
    3. Date of Earliest Transaction (Month/Day/Year)
    10/19/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A common stock 10/19/2023 S 22,837 D $0.4025(1) 286,893 I See Footnotes(2)(3)(4)
    Class A common stock 10/19/2023 S 251,902 D $0.4025(1) 2,971,128 I See Footnotes(3)(4)(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    BAKER BROS. ADVISORS LP

    (Last) (First) (Middle)
    860 WASHINGTON STREET, 3RD FLOOR

    (Street)
    NEW YORK NY 10014

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BAKER JULIAN

    (Last) (First) (Middle)
    860 WASHINGTON STREET, 3RD FLOOR

    (Street)
    NEW YORK NY 10014

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    BAKER FELIX

    (Last) (First) (Middle)
    860 WASHINGTON STREET, 3RD FLOOR

    (Street)
    NEW YORK NY 10014

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Baker Bros. Advisors (GP) LLC

    (Last) (First) (Middle)
    860 WASHINGTON STREET, 3RD FLOOR

    (Street)
    NEW YORK NY 10014

    (City) (State) (Zip)
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares of Class A common stock ("Class A common stock") of Atreca, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $0.37 to $0.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
    2. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A common stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
    3. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
    4. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
    5. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A common stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
    Remarks:
    By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 10/23/2023
    /s/ Julian C. Baker 10/23/2023
    /s/ Felix J. Baker 10/23/2023
    By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 10/23/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCEL

    DatePrice TargetRatingAnalyst
    3/4/2022$17.00 → $14.00Buy
    Stifel
    More analyst ratings

    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Atreca Inc.

      DEFM14A - Atreca, Inc. (0001532346) (Filer)

      4/22/24 9:21:58 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Atreca Inc.

      PREM14A - Atreca, Inc. (0001532346) (Filer)

      4/11/24 4:52:06 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Atreca Inc.

      15-12G - Atreca, Inc. (0001532346) (Filer)

      4/1/24 4:31:35 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome to Acquire Antibody-Related Assets and Materials from Atreca

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

      CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

      SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no

      11/14/23 4:30:08 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:50:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:37:17 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel reiterated coverage on Atreca with a new price target

      Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

      3/4/22 7:37:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Atreca with a new price target

      Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously

      6/4/21 7:01:08 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Atreca with a new price target

      Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00

      2/8/21 5:57:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

      SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a

      1/9/23 8:30:54 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

      - Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to

      6/27/22 8:00:00 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

      SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele

      6/16/22 4:05:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Atreca Inc.

      SC 13G - Atreca, Inc. (0001532346) (Subject)

      1/10/24 4:52:48 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      12/7/22 10:24:32 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      2/14/22 4:47:03 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Financials

    Live finance-specific insights

    See more
    • Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

      ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

      3/29/23 4:05:12 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

      SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

      3/23/23 5:00:36 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Expansion of Preclinical Pipeline

      Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

      4/5/22 4:01:00 PM ET
      $BCEL
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care